Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.
We have many programs currently in Phase III development. All these medicines are potentially transformative in nature. These are not ‘me too’ drugs that aim to provide incremental value. We are talking about hugely exciting, first-in-class or best-in-class, potential blockbusters
